Identification of molecular markers to diagnose high grade pre-malignant lesions (HSIL) of the uterine cervix is an exciting collaborative effort with members of our division and with TriPath Oncology, a subsidiary of TriPath Imaging. Not only will the markers enable location of rare HSIL cells on Pap tests, but they may be able to predict those women who are destined for cervical cancer without intervention. The intended goal is to accurately diagnose and avoid over treatment.
Rosenthal DL: Automation and the Endangered Future of the Pap Test (invited Commentary), JNCI 90:738-749, 1998.
ASCUS/LSIL Triage Study (ALTS)Group. Rosenthal DL, member of Pathology QC Group. Comparison of Three Management Strategies for Patients with Atypical Squamous Cells of Undetermined Significance: Baseline Results from a Randomized Trial. JNCI 93(4):293-299, 2001.
ASCUS/LSIL Triage Study (ALTS) Group. Rosenthal DL, member of Pathology QC Group. HPV DNA remains detectable longer than related cervical cytologic abnormalities. J Infect Dis 2002;186:1169-72.
Levi AW, Kelly DP, Rosenthal DL, Ronnett BM. Atypical Squamous Cells of Undetermined Significance (ASC-US) in Liquid-Based Cytologic Specimens: Results of Reflex HPV Testing and Histologic Follow-up in Routine Practice with Comparison of Interpretive and Probablistic Reporting Methods. Cancer Cytopath 2003;99:191-7.
Trimble CL, Richards LA, Wilgus-Weigweiser B, Plowden K, Rosenthal DL, Klassen A. Effectiveness of Screening for Cervical Cancer in an Inpatient Hospital Setting. Obstet Gynecol. 2004;103:310-16.